Bivictrix Therapeutics PLC - Macclesfield, England-based biotechnology company focusing on cancer therapies - Nominates a clinical candidate for its BVX001 programme after data from a clinical study into the Bi-Cygni antibody drug conjugate showed significant tumour regressions with no observed adverse effects in acute myeloid leukaemia.

BVX001 targets the cancer-specific twin antigen fingerprint of CD7+CD33+, which is present only on the leukaemic cancer cells enabling them to be selectively targeted, while leaving healthy white blood cells alone.

Chief Executive Officer Tiffany Thorn says: ‘We will continue to progress BVX001 through further preclinical studies towards obtaining regulatory approval to initiate human trials, while seeking suitable third-party partnerships to support manufacturing and clinical development activities as well as commercialisation of the asset.’

Current stock price: 13.95 pence, up 7.3% on Tuesday

12-month change: down 39%

Copyright 2023 Alliance News Ltd. All Rights Reserved.